Glucocorticosteroids rescue basophils from dasatinib-augmented immunoglobulin E-mediated histamine release.
| Autor: | Herrmann H; Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria., Blatt K, Ghanim V, Kneidinger M, Marth K, Valenta R, Valent P |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | International archives of allergy and immunology [Int Arch Allergy Immunol] 2012; Vol. 159 (1), pp. 15-22. Date of Electronic Publication: 2012 Apr 27. |
| DOI: | 10.1159/000335146 |
| Abstrakt: | Background: Dasatinib is a multikinase inhibitor active against several tyrosine kinases including ABL, KIT, Lyn and Btk. Apart from its known antileukemic activity, the drug produces several side effects including edemas and pleural effusions, which are supposedly triggered by activated immune cells. Effusion formation can be treated effectively by glucocorticosteroids. We have recently shown that low concentrations of dasatinib (<0.1 µM) promote IgE-dependent secretion of histamine in basophils, especially in allergic individuals. In the current study, we asked whether glucocorticosteroids inhibit dasatinib-induced activation of basophils. Methods: Basophils were preincubated with dexamethasone, prednisolone and hydrocortisone for 24 h, and were then exposed to an anti-IgE antibody (normal basophils) or the allergens Bet v 1 and Phl p 5 (allergic patients) with or without low concentrations of dasatinib (0.025 µM). After incubation, basophils were examined for histamine release and expression of CD63 and CD203c. Results: All three glucocorticosteroids were found to counteract IgE-dependent and dasatinib-enhanced histamine release in basophils in nonallergic and allergic individuals. In addition, glucocorticosteroids were found to inhibit anti-IgE-induced upregulation of CD63 and CD203c in the presence or absence of dasatinib. The inhibitory effects of glucocorticosteroids were dose-dependent (effective range: 1-10 µM) and seen in all donors examined. Conclusions: Glucocorticosteroids rescue IgE receptor cross-linked basophils from additional costimulatory effects of low-dose dasatinib which may have clinical implications in dasatinib-treated patients. (Copyright © 2012 S. Karger AG, Basel.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|